FlandersBio offers an up-to-date life sciences database with detailed information about all FlandersBio members.
FlandersBio beschikt over een geüpdate life sciences databank met een gedetailleerd overzicht van alle FlandersBio-ledenbedrijven.
Progress Pharma adopts a business model for asset-centric drug development, aimed at advancing pharmaceutical assets beyond POC/Phase I/Phase II. Our deepest expertise resides in gastro-enterology, pain, immunology, dermatology, urology and women’s health. We turn the asset into a venture, whose mission is to advance the asset to the next phase - or further. We create a new company around this asset, along with the asset’s originator and specialized investment funds. Each party holds a participation in the venture, reflecting its contribution and its share in the development risk. Progress Pharma conducts the due diligence, develops the development and business plans, brings the co-investors to the table and runs the project in a cost-efficient manner. When the venture has successfully led the asset through the agreed development phase, Progress Pharma paves the way for the next future of the venture – whether it is a new investment round, IPO, a trade sale or licensing … Full focus is on progressing the asset and creating value.